Q-omics provides the consensus-scored DCAF12 profile across patient tissues and cancer cell-line models. DCAF12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCAF12 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, DCAF12 RNA expression shows 19,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where DCAF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCAF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCAF12 survival associations across molecular data types. DCAF12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCAF12 RNA expression–survival associations across cancer types. High DCAF12 expression shows unfavorable associations in ACC, LIHC and THCA, but favorable associations in KIRC, OV and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DCAF12 RNA expression.
This table summarizes DCAF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in BLCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for DCAF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCAF12 shows lower tumor expression in THCA and KICH and higher tumor expression in BLCA, LUAD, STAD and LIHC. The BLCA box plot shows higher DCAF12 RNA expression in tumor versus normal tissue (log2 FC = +1.337, t-test p < 0.001).
This table shows molecular features associated with DCAF12 in patient tissues and cancer cell lines. In patient samples, DCAF12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCAF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
